Drug Database · Clinicians

Imidapril

Brands (2) Norten, VascorShow all

Angiotensin-converting enzyme inhibitors; ACE inhibitors PH FDA category

CrCl <30: half dose or longer intervalRx · Prescription drug4 PH productsVAT-exempt Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals

Contraindications

  • History of angioedema (ACE inhibitor, hereditary, acquired or idiopathic)
  • Pregnancy
  • AN69 hemodialysis; dextran sulfate or similar apheresis
  • Aliskiren with diabetes or GFR <60
  • Sacubitril/valsartan within 36 hours
  • Hypersensitivity
renalcarematters.com, reviewed

Dosing: Adult

  • Hypertension, including renal parenchymal hypertension: 5 to 10 mg once daily; start 2.5 mg in severe hypertension, kidney impairment or renal parenchymal hypertension
renalcarematters.com, reviewed

Dosing: Altered kidney function

Imidapril is an ACE inhibitor whose active metabolite is excreted in urine. The Singapore product information starts at 2.5 mg once daily in kidney impairment and, at creatinine clearance (CrCl) below 30 mL/min or serum creatinine above 3 mg/dL, advises halving the dose or extending the interval because accumulation can cause hypotension and further kidney decline. Hemodialysis with AN69 membranes is contraindicated. It has no US FDA label.

Kidney function measure: Singapore product information uses creatinine clearance (CrCl, mL/min) or serum creatinine (above 3 mg/dL).

Show full dosing details
CrCl ≥60 mL/min
Usual: 5 to 10 mg once daily (Singapore NDF).
CrCl 30–59 mL/min
Hypertension with kidney impairment: start 2.5 mg once daily and titrate (Singapore NDF). Monitor potassium and creatinine.
CrCl 15–29 mL/min
CrCl <30 mL/min (or serum creatinine above 3 mg/dL): use with care; consider halving the usual dose or extending the dosing interval. Start at 2.5 mg once daily in hypertension with kidney impairment (Singapore NDF). Monitor potassium and creatinine.
CrCl <15 mL/min (not on dialysis)
CrCl <30 mL/min (or serum creatinine above 3 mg/dL): use with care; consider halving the usual dose or extending the dosing interval. Start at 2.5 mg once daily in hypertension with kidney impairment (Singapore NDF). Monitor potassium and creatinine.
Hemodialysis (intermittent)
Hemodialysis with AN69 (polyacrylonitrile) membranes is contraindicated (anaphylactoid reactions). Dose as for CrCl <30 (half dose or longer interval); no dialysis-specific dosing given (Singapore NDF).
Peritoneal dialysis
Dose as for CrCl <30; no PD-specific data.
CRRT
No data; avoid starting ACE inhibitors in acute kidney injury.
  • Dialyzable? Not stated.
  • Monitoring Potassium and creatinine after starting and dose changes; blood pressure (excess hypotension); angioedema (Singapore NDF). Recheck creatinine and potassium after starting or increasing the dose; continue unless creatinine rises by more than 30% within 4 weeks, and investigate larger rises (renal artery stenosis, volume depletion, NSAIDs). Continue even when eGFR falls below 30 unless not tolerated (KDIGO 2024).
Children (kidney dosing)
eGFR ≥60
Not established in children; kidney dosing not applicable.
eGFR 30–59
Not established in children; kidney dosing not applicable.
eGFR 15–29
Not established in children; kidney dosing not applicable.
eGFR <15 (not on dialysis)
Not established in children; kidney dosing not applicable.
Hemodialysis (intermittent)
Not established in children; kidney dosing not applicable.
Peritoneal dialysis
Not established in children; kidney dosing not applicable.
CRRT
Not established in children; kidney dosing not applicable.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

Source: Singapore NDF product information (October 9, 2026). This generic has no US FDA label.

Dosing: Pediatric

Approved ages
Not stated in the source.
Usual dose
Not established.

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed

Dosage forms

Philippines

  • Tablet: 5 mg, 10 mg

Registered products in the Philippines

4 products registered with the Food and Drug Administration (FDA) Philippines list Imidapril as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products4
Philippine FDA-registered products for Imidapril
Package insert
NortenImidapril Hydrochloride
10 mg TabletFlex foil Strip x 10's Box of 100's
RxVAT-exempt
Amherst Laboratories, Inc.Philippines
Trader: UNILAB, INC.
DR-XY23294
Jul 6, 2028
NORTENImidapril Hydrochloride
5 mg TabletAluminum Foil Strip x 10's Box of 100's
RxVAT-exempt
Amherst Laboratories, Inc.Philippines
Trader: UNILAB, INC.
DR-XY23293
Sep 14, 2027
VascorImidapril Hydrochloride
10 mg TabletFoil Strip x 10's (Box of 100's)
RxVAT-exempt
Amherst Laboratories, Inc.Philippines
Trader: UNILAB, Inc.
DR-XY23799
Jul 6, 2028
VascorImidapril Hydrochloride
5 mg TabletFoil Strip x 10's (Box of 100's)
RxVAT-exempt
Amherst Laboratories, Inc.Philippines
Trader: UNILAB, Inc.
DR-XY23798
Jul 26, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Drug interactions

Drug or classSeverityEffectWhat to do
Aliskiren (diabetes or GFR <60)AvoidStroke, kidney impairment, hyperkalemia, hypotension.Contraindicated unless blood pressure is markedly uncontrolled.
Sacubitril/valsartanAvoidAngioedema.Contraindicated; separate by 36 hours.
AN69 dialysis membranes; dextran sulfate LDL apheresisAvoidAnaphylactoid reactions, shock.Contraindicated.
Potassium-sparing diuretics, mineralocorticoid receptor antagonists, potassium supplements, salt substitutes, trimethoprimAdjust or monitorHyperkalemia.Monitor potassium.
NSAIDs including COX-2 inhibitorsAdjust or monitorAcute kidney injury; less blood-pressure effect.Avoid regular use; monitor creatinine.
LithiumAdjust or monitorHigher lithium levels.Monitor lithium levels.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed

Adverse reactions

Common

  • Dry cough (ACE inhibitor class effect)

Serious

  • Angioedema
  • Hyperkalemia; worsening kidney function
  • Excessive hypotension
renalcarematters.com, reviewed

Monitoring parameters

  • Potassium and creatinine after starting and dose changes; blood pressure (excess hypotension); angioedema (Singapore NDF). Recheck creatinine and potassium after starting or increasing the dose; continue unless creatinine rises by more than 30% within 4 weeks, and investigate larger rises (renal artery stenosis, volume depletion, NSAIDs). Continue even when eGFR falls below 30 unless not tolerated (KDIGO 2024). Kidney
  • Potassium, creatinine, blood pressure
renalcarematters.com, reviewed

Pharmacokinetics

Key PK parameters

Active metabolitesImidaprilat
Renal excretion kidneyUrinary (reduced in kidney impairment); percentage not stated
Dialyzability kidneyNot stated
renalcarematters.com, reviewed

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Ministry of Health Singapore (National Drug Formulary). Tanatril tablets 10 mg product information (SIN10614P) [Singapore NDF product information, October 9, 2026; no US FDA label]. https://www.ndf.gov.sg/about-drugs/product-information/SIN10614P/
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. Ministry of Health Singapore. (2026). Tanatril tablets 10 mg (imidapril hydrochloride) [SIN10614P; National Drug Formulary product information; last updated October 9, 2026]. https://www.ndf.gov.sg/about-drugs/product-information/SIN10614P/
  4. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. (2024). KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International, 105(4S), S117–S314. https://doi.org/10.1016/j.kint.2023.10.018

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .